Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.34 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1733172 | 0.88 | SMYD2 (0.33) | SMYD2ALKCYP3A4HTTSMN1; SMN2 | |
| SCHEMBL31092036 | 0.85 | SMYD2 (0.37) | SMYD2ALKCYP3A4HTTSMN1; SMN2 | |
| SCHEMBL13093647 | 0.84 | SMYD2 (0.35) | SMYD2CYP3A4HTTSMN1; SMN2KDM4E | |
| SCHEMBL17093480 | 0.84 | SMYD2 (0.34) | SMYD2ALKCYP3A4HTTSMN1; SMN2 | |
| SCHEMBL3638318 | 0.83 | SMYD2 (0.36) | SMYD2ALKCYP3A4HTTSMN1; SMN2 | |
| SCHEMBL10422857 | 0.83 | KDM4E (0.35) | SMYD2ALKCYP3A4KDM4E | |
| SCHEMBL13778495 | 0.82 | SMYD2 (0.34) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL1733644 | 0.81 | SMYD2 (0.33) | SMYD2ALKCYP3A4HTTSMN1; SMN2 | |
| SCHEMBL2482570 | 0.81 | SMYD2 (0.34) | SMYD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL4337460 | 0.80 | SMYD2 (0.33) | SMYD2CYP3A4HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4626481-A1 | NOVEL LINKER DRUGS COMPRISING PHOSPHOANTIGENS, NOVEL CONJUGATES AND THEIR USE IN THERAPY | Byondis B.V. (NL) | 2025-10-08 | — | — | EP | disclosed |
| WO-2024133374-A1 | NOVEL LINKER DRUGS COMPRISING PHOSPHOANTIGENS, NOVEL CONJUGATES AND THEIR USE IN THERAPY | BYONDIS B.V. (NL) | 2024-06-27 | — | — | WO | disclosed |
| EP-3328859-B1 | 3-((4-ISOQUINOLIN-3-YL)METHYL)-1H-IMIDAZO[4,5-C]PYRIDIN-2(3H)-ONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF REPLICATION OF THE RESPIRATORY SYNCYTIAL VIRUS (RSV) | BOEHRINGER INGELHEIM INT (DE) | 2020-06-03 | — | — | EP | disclosed |
| US-20190002436-A1 | RESPIRATORY SYNCYTIAL VIRUS INHIBITORS | MEDIVIR AB (SE) | 2019-01-03 | — | — | US | disclosed |
| EP-3328859-A1 | RESPIRATORY SYNCYTIAL VIRUS INHIBITORS | Medivir AB (SE) | 2018-06-06 | — | — | EP | disclosed |
| WO-2017018924-A1 | RESPIRATORY SYNCYTIAL VIRUS INHIBITORS | MEDIVIR AB (SE) | 2017-02-02 | — | — | WO | disclosed |
| US-20130078256-A1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2013-03-28 | — | — | US | disclosed |
| US-8334295-B2 | Pyrimidine derivatives as HIV reverse transcriptase inhibitors | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-12-18 | — | — | US | disclosed |
| US-8168666-B2 | Substituted carbinol compound | KOWA COMPANY, LTD. (JP) | 2012-05-01 | — | — | US | disclosed |
| US-8168666-B2 | Substituted carbinol compound | KOWA COMPANY, LTD. (JP) | 2012-05-01 | — | — | US | disclosed |
| EP-2098515-B1 | SUBSTITUTED CARBINOL COMPOUND | KOWA CO (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20110076276-A1 | Novel HIV reverse transcriptase inhibitors | GILEAD SCIENCES, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| US-20100063119-A1 | SUBSTITUTED CARBINOL COMPOUND | KOWA COMPANY, LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100063119-A1 | SUBSTITUTED CARBINOL COMPOUND | KOWA COMPANY, LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
| EP-2098515-A1 | SUBSTITUTED CARBINOL COMPOUND | Kowa Company. Ltd. (JP) | 2009-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002436-A1 | RESPIRATORY SYNCYTIAL VIRUS INHIBITORS | NR0B1, NR1I3, SCARB1 | SMYD2 1910/4885ALK 2834/4885CYP3A4 864/4885 |
| US-20110076276-A1 | Novel HIV reverse transcriptase inhibitors | POLR2E, POLR1E, POLR2H | SMYD2 2398/4885ALK 3907/4885CYP3A4 1208/4885 |
| US-20130078256-A1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | POLR2E, POLR1E, POLR2H | SMYD2 2398/4885ALK 3907/4885CYP3A4 1208/4885 |
| US-20100063119-A1 | SUBSTITUTED CARBINOL COMPOUND | NR1H2, NR1H3, CYP46A1 | SMYD2 2590/4885ALK 2530/4885CYP3A4 2231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.